Why do women seem to embrace hemp medicine more than men? The answer goes deeper than wellness trends, it lies in biology. Women and hemp share a natural synergy that science is only beginning to fully understand.

Our bodies, especially the endocannabinoid system (ECS), are built to respond differently to cannabinoids and other natural compounds in hemp, and growing research shows that gender may play a critical role in shaping your overall hemp experience. For women, this means CBD and hemp medicine may offer unique benefits that men do not experience in the same way.

Science supports this biological difference. A 2025 study published in Preventive Medicine Reports found that females were 42% more likely to use CBD than males. The same research also revealed that adults had higher odds of CBD use compared to adolescents, suggesting that as women age, their reliance on hemp medicine grows. Researchers believe the connection comes down to the interplay between the ECS and female hormones like estrogen and progesterone. These hormones not only regulate reproductive health, but also influence mood, stress response, and even how pain is perceived. When combined with cannabinoids, they can amplify or change the way hemp medicine works, making CBD for women uniquely effective during menstruation, pregnancy, or menopause.

The Endocannabinoid System and Gender Differences

Overview of the Endocannabinoid System (ECS)

The endocannabinoid system (ECS) is one of the body’s most important regulators, working quietly in the background to maintain balance, or homeostasis. Dr. Ethan Russo describes it as an essential regulator of bodily function in its many facets. 

The ECS is made up of three components known as endocannabinoids, cannabinoid receptors and enzymes. Endocannabinoids are naturally occurring compounds produced by the body. Interestingly, they share structural similarities with hemp-based cannabinoids like CBD, CBDa, CBG, and THC, which is why hemp medicine can so effectively influence the ECS. These endocannabinoids act as chemical messengers, helping to regulate mood, pain, stress response, immune activity, and sleep cycles. Cannabinoid receptors are the “docking stations” of the ECS. They are located throughout the brain and body, most notably as CB1 receptors in the nervous system and CB2 receptors in the immune system. When endocannabinoids, or hemp-derived compounds such as CBDa, interact with these receptors, they help restore balance to processes that may be out of sync. Enzymes complete the cycle by breaking down endocannabinoids once their job is done, ensuring the system stays finely tuned.

Think of the ECS as a communication network that helps different systems in the body work together. It influences mood, stress response, sleep cycles, pain perception, immune function, and even appetite. When the ECS is balanced, the body feels and functions better. When it’s out of balance, discomfort, stress, or disrupted sleep can appear.

This is where hemp comes in. Cannabinoids such as CBD and CBDa interact with ECS receptors, helping the body return to a state of balance. Unlike THC, which binds directly to ECS receptors, CBD and CBDa works by modulating their activity and supporting the system’s natural processes. 

How the Endocannabinoid System Differs Between Men and Women

While the endocannabinoid system functions similarly across all humans, it does not operate in a one-size-fits-all manner. It varies not only from person to person but also between genders. Research shows that the ECS in females differs from the ECS in males in three important ways: receptor distribution and activity, hormonal fluctuations, and enzyme activity. Let’s dive into each of these.

• Receptor distribution and activity 

One of the biggest differences in how men and women respond to hemp lies in the way their bodies distribute cannabinoid receptors. Cannabinoid receptors are the “docking stations” that interact with CBD, CBDa and other cannabinoids. There are two main types: CB1 receptors, mostly found in the brain and central nervous system, and CB2 receptors, which are more common in the immune system.

Information from a 2010 research shows that women often have more CB1 receptors in certain parts of the brain, like the amygdala, which helps regulate emotions. This difference is mostly influenced by estrogen and even appears stronger in younger females, suggesting that hormones shape how the endocannabinoid system works from an early age.

These differences don’t just exist on paper; they show up in real life. Studies from 2001 and 2008 have found that women are more sensitive to the pain-relieving and calming effects of cannabinoids, while men are more likely to experience increased appetite and weight gain. Even when women have fewer receptors at certain stages, their receptors often work more efficiently, making them more responsive to hemp-based medicine. Another 2010 research discovered that despite having lower receptor density at some stages, adolescent females demonstrated higher G protein activation after CB1 stimulation in several brain areas, which suggests their receptors may be more efficient.

As people age, these patterns continue to diverge. Research from a 2008 paper shows that between ages 45 and 70, men tend to lose or maintain their receptor levels, while women actually gain more CB1 receptors throughout the brain. This may help explain why women often report stronger effects from CBD for stress, mood, or pain relief, whereas men more often experience effects tied to appetite and inflammation.

Adding to this complexity, components of the ECS are distributed throughout the female reproductive system, including the ovaries, fallopian tubes, myometrium, and endometrium, highlighting how closely hemp compounds like CBD, CBDa and CBG can interact with female reproductive health and hormonal balance.

• Hormonal influence/fluctuations 

Hormones play a powerful role in how the endocannabinoid system (ECS) works, especially in women. Estrogen and progesterone, two key female hormones, directly influence the production of endocannabinoids, the sensitivity of cannabinoid receptors, and even how quickly enzymes break them down. Research shows that while estrogen generally increase sensitivity to hemp, progesterone decreases this activity. In other words, shifts in hormone levels can change how strongly women feel the effects of hemp-based compounds like CBD, CBDa, or CBG.

During the menstrual cycle, rising and falling estrogen levels can make the ECS more or less active. This helps explain why some women notice stronger relief from CBD for mood swings, cramps, or stress at certain times of the month. Research also suggests that women may metabolize cannabinoids differently depending on their cycle phase, which can lead to more noticeable effects during periods of higher estrogen activity.

Pregnancy introduces another major shift in how the endocannabinoid system (ECS) functions. The ECS plays an important role in fertility and reproductive health, and cannabinoid receptors are found in the ovaries, uterus, and placenta. A research paper published in the International Journal of Molecular Sciences shows that the ECS is deeply involved in regulating both male and female reproductive processes, including gametogenesis, fertility, fertilization, implantation, embryonic and fetal development, gonadal maturation, libido, and lactation.

Later in life, during menopause, declining estrogen levels once again reshape the ECS. Many women report increased benefits from CBD for sleep, joint comfort, and mood support during this transition, likely because the ECS adapts to the loss of hormonal balance.

For women, these natural hormonal fluctuations create a unique and dynamic relationship with hemp. Rather than being static, the ECS is constantly shifting, which makes women’s responses to cannabinoids different from men’s and even different from one stage of life to another.

• Enzyme activity 

The third key difference in the endocannabinoid system (ECS) between men and women is how enzymes work to regulate cannabinoids. Enzymes are responsible for breaking down endocannabinoids once they have done their job, keeping the system balanced. The two most important are FAAH (fatty acid amide hydrolase), which breaks down the endocannabinoid anandamide, and MAGL (monoacylglycerol lipase), which degrades 2-AG.

Research shows that FAAH activity is influenced by sex hormones such as estrogen. In women, higher estrogen levels are linked with lower FAAH activity, meaning that endocannabinoids like anandamide stay active in the body for longer. This can enhance mood regulation, stress relief, and even fertility, and it also helps explain why CBD for women may feel especially effective at certain times of the menstrual cycle. By contrast, men often maintain more stable enzyme activity, which can lead to less fluctuation in their response to cannabinoids.

During pregnancy and menopause, shifts in hormone levels can also alter enzyme activity, further influencing how hemp-based compounds interact with the body. These enzyme differences, combined with receptor distribution and hormonal cycles, create a unique hemp gender response, where women may experience stronger or longer-lasting effects from cannabinoids than men.

Practical Applications of Hemp Medicine for Women

The science of the endocannabinoid system shows us why many women report unique benefits from hemp medicine. By working in sync with hormonal rhythms and receptor patterns, cannabinoids like CBD, CBDa, and CBG can support women in several key areas of health and wellness.

• Menstrual Health and Pain Relief

Menstrual cycles often bring cramps, bloating, and discomfort. Hemp compounds interact with CB1 and CB2 receptors to help regulate pain signaling and inflammation, offering natural relief that feels gentler than over-the-counter medications. Many women also find that CBD helps reduce mood swings tied to PMS.

• Mood Balance and Anxiety Support

Fluctuating estrogen and progesterone levels can impact emotional stability. Research suggests that CBD supports serotonin receptors in the brain, which play a role in mood regulation. Women experiencing stress, anxiety, or emotional shifts during their cycle may benefit from the calming effects of hemp.

• Improved Sleep Quality

Poor sleep is a common concern for women, particularly during menstruation or menopause. CBD and CBG show potential in reducing nighttime restlessness by calming overactive neural activity, which can help restore healthy sleep cycles.

• Menopause Support

During menopause, estrogen levels drop, which can impact the ECS. This may contribute to hot flashes, mood swings, or bone density loss. Hemp medicine may offer supportive relief by helping regulate temperature, mood, and inflammation naturally.

• Reproductive Health and Fertility

The ECS is active in the ovaries, fallopian tubes, uterus, and endometrium. This means hemp-based compounds could play a role in supporting reproductive health. While more research is needed, early evidence suggests potential benefits for conditions linked to inflammation and hormonal imbalance.

Frontiers in Psychiatry. (2024). Patterns and predictors of cannabidiol (CBD) use in the United States: Results from the 2023 National Survey on Drug Use and Health. Frontiers in Psychiatry, 15, 11795096. https://pmc.ncbi.nlm.nih.gov/articles/PMC11795096/

Russo, E. B. (2020). Introduction to the endocannabinoid system (Revised January 2020). https://ethanrusso.org/wp-content/uploads/2020/02/Russo-Introduction-to-the-Endocannabinoid-System-Revised-January-2020.pdf

Rubino, T., Realini, N., Castiglioni, C., Guidali, C., Viganò, D., Marras, E., Petrosino, S., Perletti, G., Maccarrone, M., Di Marzo, V., & Parolaro, D. (2008). Role in anxiety behavior of the endocannabinoid system in the prefrontal cortex. Neuropsychopharmacology, 33(7), 1570–1580. https://www.sciencedirect.com/science/article/abs/pii/S0306453010000533

Tseng, A. H., & Craft, R. M. (2001). Sex differences in antinociceptive and motoric effects of cannabinoids. European Journal of Pharmacology, 430(1), 41–47. https://www.sciencedirect.com/science/article/abs/pii/S0014299901012675

Craft, R. M., Marusich, J. A., & Wiley, J. L. (2007). Sex differences in cannabinoid pharmacology: A reflection of differences in the endocannabinoid system? Life Sciences, 80(5), 474–481. https://www.sciencedirect.com/science/article/abs/pii/S0014299907009934

Burston, J. J., Wiley, J. L., Craig, A. A., Selley, D. E., & Sim-Selley, L. J. (2010). Regional enhancement of cannabinoid CB1 receptor desensitization in female adolescent rats. Frontiers in Behavioral Neuroscience, 4, 64. https://www.frontiersin.org/journals/behavioral-neuroscience/articles/10.3389/fnbeh.2011.00064/full

Van Laere, K., Goffin, K., Casteels, C., Dupont, P., Mortelmans, L., de Hoon, J., Bormans, G., & Versijpt, J. (2008). Gender-dependent increases with healthy aging of the human cerebral cannabinoid-type 1 receptor binding using [18F]MK-9470 PET. NeuroImage, 39(4), 1533–1541. https://www.sciencedirect.com/science/article/abs/pii/S1053811907009887

Maccarrone, M., Guzmán, M., Mackie, K., Doherty, P., & Harkany, T. (2014). Programming of neural cells by (endo)cannabinoids: From physiological rules to emerging therapies. Nature Reviews Neuroscience, 15(12), 786–801. https://anatomypubs.onlinelibrary.wiley.com/doi/10.1002/ar.21181

Hill, M. N., & Patel, S. (2013). Translational evidence for the involvement of the endocannabinoid system in stress-related psychiatric illnesses. Biology of Mood & Anxiety Disorders, 3(1), 19. https://pmc.ncbi.nlm.nih.gov/articles/PMC2601032/

Hillard, C. J., Weinlander, K. M., & Stuhr, K. L. (2012). Contributions of endocannabinoid signaling to psychiatric disorders in humans: Genetic and biochemical evidence. Neuroscience, 204, 207–229. https://pmc.ncbi.nlm.nih.gov/articles/PMC3221102/

Wenger, T., Ledent, C., Csernus, V., Gerendai, I., & Zimmer, A. (2003). The central cannabinoid receptor inactivation suppresses endocrine reproductive functions. Endocrinology, 144(10), 4296–4303. https://pubmed.ncbi.nlm.nih.gov/20369362/

Battista, N., Pasquariello, N., Di Tommaso, M., & Maccarrone, M. (2012). Interplay between endocannabinoids, steroids, and cytokines in the control of human reproduction. Journal of Neuroendocrinology, 24(6), 843–859. https://pmc.ncbi.nlm.nih.gov/articles/PMC4918871/

Craft, R. M. (2005). Sex differences in behavioral effects of cannabinoids. European Journal of Pharmacology, 493(1–3), 251–260. https://pmc.ncbi.nlm.nih.gov/articles/PMC2931555/

Mouslech, Z., & Valla, V. (2009). Endocannabinoid system: An overview of its potential in current medical practice. International Journal of Molecular Sciences, 10(9), 3389–3409. https://www.mdpi.com/1422-0067/26/15/7095

Hermann, H., Marsicano, G., & Lutz, B. (2002). Coexpression of the cannabinoid receptor type 1 with dopamine and serotonin receptors in distinct neuronal subpopulations of the adult mouse forebrain. Neuroscience, 109(3), 451–460. https://www.sciencedirect.com/science/article/abs/pii/S0306453007000303